Edition:
United Kingdom

AB Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

8.46EUR
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
€8.46
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
86,018
52-wk High
€18.07
52-wk Low
€7.53

Select another date:

Tue, Nov 21 2017

BRIEF-AB Science announces publication of preclinical data showing that masitinb is capable of counteracting resistance to oncology treatments

* REG-AB SCIENCE ANNOUNCES THE PUBLICATION OF PRECLINICAL DATA SHOWING THAT MASITINB IS CAPABLE OF COUNTERACTING RESISTANCE TO ONCOLOGY TREATMENTS

BRIEF-AB science announces ‍preclinical data showing protective effect of masitinib

* ‍PRECLINICAL DATA SHOWING PROTECTIVE EFFECT OF MASITINIB ON PERIPHERAL NERVOUS SYSTEM IN ALS PUBLISHED IN JOURNAL OF CLINICAL INVESTIGATION INSIGHT​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-AB Science: CHMP adopts negative opinion for Masitinib marketing authorization

* REG-AB SCIENCE ANNOUNCES THAT CHMP ADOPTED A NEGATIVE OPINION FOR MASITINIB MARKETING AUTHORIZATION IN INDOLENT SYSTEMIC MASTOCYTOSIS AFTER REASSESSMENT

BRIEF-AB Science net loss narrows to 13.5 million euros

* NET LOSS OF 13.5MEUR IN FIRST HALF OF 2017, A DECREASE OF 8.4% AS COMPARED WITH FIRST HALF OF 2016 (14.7MEUR )

BRIEF-AB Science announces issuance of a new european patent

* REG-AB SCIENCE ANNOUNCES ISSUANCE OF A NEW EUROPEAN PATENT FOR PROTECTING THE USE OF MASITINIB IN PANCREATIC CANCER PATIENTS

BRIEF-AB Science presents supportive data from its phase 3 study in severe systemic mastocytosis

* PRESENTS SUPPORTIVE DATA FROM ITS PHASE 3 STUDY IN SEVERE SYSTEMIC MASTOCYTOSIS Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: